NuGen Medical Devices Azioni (OTC: NGMDF)

Ultime notizie per NuGen Medical Devices (OTC:NGMDF) Azioni

NuGen Medical Devices Inc is a medical device manufacturing company specializing in the field of needleless injections and related technologies. The reportable segment of the company is the manufacturing of needle injector devices. Geographically, the company generates revenue from Europe, followed by Asia, North America, and other.

NUGEN MED DEVICES INC by NUGEN MED DEVICES INC.

NuGen Medical Devices Inc

News

BlackBerry's QNX And Vector Sign MoU To Jointly Develop And Deliver Foundational Vehicle Software Platform

Signs of a Peak? Here&#8217;s What Adhishthana Tells Us!
Roper Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is currently in Phase 10 of its 18-Phase Adhishthana Cycle, and while the stock remains in ascent, there are early signs that a peak may be forming. Let's break down what the structure reveals under the lens of the Adhishthana Principles.
<h3 class="wp-block-heading">Alignment With Adhishthana Principles</h3>
So far, Roper has shown a strong 88.88% alignment with the Adhishthana framework, our proprietary cyclical model based on behavioral archetypes, quantitative signals, and timing cycles.
<h3 class="wp-block-heading">Roper&#8217;s Monthly Chart Structure: Trouble Brewing?</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="604" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23045303/Roper-Technologies-Monthly-Chart-Adhishthana.png" alt="Fig.1 Roper Technologies Monthly Chart (Source: Adhishthana.com)" class="wp-image-14722" style="width:773px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23045303/Roper-Technologies-Monthly-Chart-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23045303/Roper-Technologies-Monthly-Chart-Adhishthana-300x151.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23045303/Roper-Technologies-Monthly-Chart-Adhishthana-1024x515.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23045303/Roper-Technologies-Monthly-Chart-Adhishthana-768x387.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 Roper Technologies Monthly Chart (Source: Adhishthana.com)</figcaption></figure>
In Phase 9, Roper broke out of its Cakra and staged a supreme move, rallying ~73%. That marked the beginning of its Adhishthana Himalayan ascent, which has continued into Phase 10, where the stock has already gained ~41%.
But here's the key concern:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"The 18th interval is expected to be the level of peak formation; if not, then the 23rd interval. If this phase concludes without forming the peak, it is anticipated to occur in the following phases." — Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
For Roper, the recent price action aligns closely with the 18th bar of Phase 10, historically a common point for peak formation per the principles. While the bullish structure hasn't broken yet, the timing of this potential peak raises caution.
Phase 10 concludes on 2 August 2026. If the top was indeed formed at $595.17, Roper may fail to reclaim that level, initiating the descent of the Adhishthana Himalayan formation. Potentially revisiting the Phase 9 mid and low levels.
Currently, Phase 9 high ($505) has acted as a key support level, having been tested twice in Phase 10. Should the stock hold above $505, the peak may instead form in Phase 11, which would still be followed by a notable correction, per Adhishthana norms.
<h3 class="wp-block-heading">Roper&#8217;s Weekly Chart View: Caution Ahead</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="490" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23045400/Roper-Technologies-Phase-9-Weekly-Cakra-.png" alt="Fig.2 Roper Technologies Weekly Chart (Source: Adhishthana.com)" class="wp-image-14723" style="width:749px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23045400/Roper-Technologies-Phase-9-Weekly-Cakra-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23045400/Roper-Technologies-Phase-9-Weekly-Cakra--300x123.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23045400/Roper-Technologies-Phase-9-Weekly-Cakra--1024x418.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23045400/Roper-Technologies-Phase-9-Weekly-Cakra--768x314.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.2 Roper Technologies Weekly Chart (Source: Adhishthana.com)</figcaption></figure>
On the weekly chart, Roper is currently in Phase 9, a stage that typically precedes a supreme breakout move, but that breakout hasn't materialized. Instead, the stock continues to trade within the Cakra it has been forming since Phase 4.
Currently, the Lower bound of the Cakra is at $520–$525. A breakdown below this level would be a major red flag, indicating a breakdown below $505. 
If a Phase 10 peak has already been created on the monthly chart, and the stock breaks its Cakra on the weekly timeframe, it may trigger the Move of Pralay, a rapid and fierce bearish move characterized by steep corrections.
<h3 class="wp-block-heading">Conclusion: Stay Alert, Not Aggressive</h3>
<ul class="wp-block-list">
<li>If Roper holds above $505 through Phase 10, there&#8217;s room for further strength. </li>
<li>However, odds are stacked toward a peak already being in place. </li>
<li>Existing longs should be cautious and consider protective hedges. </li>
<li>New entries are not advised at this stage; wait for the structure to confirm stability. </li>
</ul>
Bottom Line: Watch $505 like a hawk. If that level gives out, all hell could break loose.

Equities

Technicals

Opinion

Signals

Trading Ideas

Is Roper Technologies Stock Signaling A Peak?

Digital asset investment products defied global turbulence last week, raking in $1.24 billion in fresh inflows—marking a tenth straight week of gains—even as crypto prices dipped and <a href="https://www.benzinga.com/news/politics/25/06/46044009/us-iran-tensions-escalate-as-iran-threatens-hormuz-closure-potentially-rattling-global-oil-markets">geopolitical tensions surged</a>.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell below $100,000 over the weekend, while the second-largest crypto by market cap, Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), fell below $2,150 after the U.S. <a href="https://www.benzinga.com/news/politics/25/06/46043708/us-airstrike-on-iran-draws-varied-reactions-from-business-leaders-bill-ackman-says-thank-you-to-our">struck Iran&#8217;s nuclear facilities</a>. Iran is expected to blockade the Strait of Hormuz, the world&#8217;s most sensitive oil shipping chokepoint, <a href="https://www.benzinga.com/markets/commodities/25/06/46046982/oil-prices-could-surge-by-10-as-us-drops-bunker-buster-bombs-on-iran-but-may-not-last-says-analyst-freight-disruptions-will-be-the-story-to-watch">spiking oil prices</a>.
The continued capital inflow into crypto markets comes as the war between <a href="https://www.benzinga.com/news/politics/25/06/46041118/iran-halts-nuclear-talks-with-us-no-negotiations-until-israeli-aggression-stops-says-foreign-minister">Iran and Israel intensifies</a>. 
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46049694/uber-kkr-rocket-companies-and-an-industrial-stock-on-cnbcs-final-trades">Uber, KKR, Rocket Companies And An Industrial Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a>
The U.S. West Texas Intermediate rose 0.92% to $75.86 a barrel, marking a five-month high.
Digital asset investment products recorded their 10th consecutive week of inflows, totaling $1.24 billion last week and pushing year-to-date (YTD) inflows to a new high of $15.1 billion, CoinShares Head of Research James Butterfill <a href="https://blog.coinshares.com/volume-239-digital-asset-fund-flows-weekly-report-95db5dc90500">wrote</a>.
Bitcoin continued to dominate investor interest, attracting $1.1 billion in inflows despite recent price corrections. 
Ethereum followed with $124 million, extending its nine-week inflow streak to a cumulative $2.2 billion, the longest since mid-2021. 
<ul class="wp-block-list">
<li>The U.S. led with $1.25 billion in new investments.</li>
<li>Canada, $20.9 million</li>
<li>Germany, $10.9 million in inflows, respectively. </li>
<li>Hong Kong and Switzerland experienced outflows of $32.6 million and $7.7 million, respectively.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46031338/ai-wont-fix-everything-veles-finance-coo-warns-against-blind-faith-in-crypto-automation">&#8216;AI Won&#8217;t Fix Everything&#8217;: Veles Finance COO Warns Against Blind Faith In Crypto Automation</a>
Butterfill noted, &#8220;The surge in activity earlier in the week tapered off in the latter half, likely due to the US Juneteenth holiday and emerging reports of US involvement in the Iran conflict.&#8221;
Short-Bitcoin products saw minor outflows of $1.4 million, suggesting investors remain optimistic about the market's direction.
Notably, the recent surge in investment interest was accompanied by significant moves from corporate players. 
Japan's Metaplanet announced it had purchased an additional 1,111 Bitcoin, bringing its total holdings to 11,111 BTC. 
The company's CEO, Simon Gerovich, confirmed that Metaplanet acquired the latest batch at $106,408 per Bitcoin. 
The firm has invested approximately $1.07 billion across all its purchases, securing its holdings at an average price of $95,869 per Bitcoin.
At current market rates, Metaplanet's Bitcoin treasury is valued at around $1.12 billion. 
The company's recent acquisition came just a week after it surpassed its initial 2025 goal of holding 10,000 BTC. 
This milestone elevated Metaplanet to the ninth-largest corporate Bitcoin holder globally, overtaking Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>).
Metaplanet has since updated its targets, aiming to accumulate 30,000 BTC by the end of 2025, 100,000 BTC by 2026, and 210,000 BTC by 2027, signaling its aggressive long-term crypto strategy.
In addition to Bitcoin and Ethereum, smaller inflows were recorded for Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) ($2.78 million) and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) ($2.69 million) last week.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46025230/why-a-public-healthcare-firm-wants-to-hold-more-bitcoin-than-most-countries">Why A Public Healthcare Firm Wants To Hold More Bitcoin Than Most Countries</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

$XRP

COIN

Investors Poured Billions Into Bitcoin And Ethereum Even As Iran-Israel Tensions Escalated

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Contracts

CTRI

Centuri Announces Over $575M In Customer Awards Across US

WIIM

QUBT

Quantum Computing shares are trading lower after the company announced a $200 million private placement of 14 million shares at $14.25 per share.

CRML

Critical Metals Signs $2M Diamond Drilling Contract With Drilling Contractors In Greenland, For Drilling Program To Increase Resource Size At Tanbreez Project

Barrington Research analyst Michael Petusky initiates coverage on Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Outperform rating and announces Price Target of $16.

Price Target

Initiation

Analyst Ratings

OFIX

Barrington Research Initiates Coverage On Orthofix Medical with Outperform Rating, Announces Price Target of $16

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the information technology sector.
<h3 class="wp-block-heading">JinkoSolar Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 13.12%</li>
<li>UBS analyst Jon Windham maintained a Neutral rating and cut the price target from $25 to $22 on March 27, 2025. This analyst has an accuracy rate of 60%.</li>
<li>GLJ Research analyst Gordon Johnson maintained a Sell rating and slashed the price target from $13.08 to $10.95 on Jan. 23, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On April 29, the solar module manufacturer's revenue decreased 39.9% year-over-year to $1.908 billion, beating the analyst consensus estimate of $1.89 billion. Adjusted loss per ADS of $2.86 missed the analyst consensus loss estimate of $1.38.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest JKS <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623"><img loading="lazy" decoding="async" width="912" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062044/image-328.png" alt="" class="wp-image-957925" style="width:607px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062044/image-328.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062044/image-328-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062044/image-328-768x691.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.80%</li>
<li>Wells Fargo analyst Aaron Rakers maintained an Underweight rating and cut the price target from $35 to $25 on May 29, 2025. This analyst has an accuracy rate of 84%.</li>
<li>Citigroup analyst Asiya Merchant maintained a Neutral rating and lowered the price target from $29 to $27.5 on May 29, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On May 28, HP reported worse-than-expected second-quarter adjusted EPS results and issued third-quarter adjusted EPS guidance below estimates.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest HPQ <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623"><img loading="lazy" decoding="async" width="927" height="851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062146/image-329.png" alt="" class="wp-image-957926" style="width:607px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062146/image-329.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062146/image-329-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062146/image-329-768x705.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h3 class="wp-block-heading">Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.43%</li>
<li>Goldman Sachs analyst Eric Sheridan maintained a Buy rating and lowered the price target from $26 to $22.5 on April 14, 2025. This analyst has an accuracy rate of 78%.</li>
<li>TD Cowen analyst Lance Vitanza maintained a Buy rating and raised the price target from $25 to $28 on Oct. 30, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On May 28, Opera announced Opera Neon, the first AI agentic browser.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest OPRA <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623"><img loading="lazy" decoding="async" width="905" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062232/image-330.png" alt="" class="wp-image-957927" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062232/image-330.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062232/image-330-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23062232/image-330-768x715.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

OPRA

Wall Street's Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields

IGC Pharma, Inc. ("IGC", or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) today announced the addition of a new clinical trial site at Tekton Research in Yukon, Oklahoma, for its Phase 2 CALMA study evaluating IGC-AD1 for agitation in Alzheimer's dementia. This expansion into the Oklahoma City metropolitan area underscores IGC's commitment to diversifying its trial population and addressing regional healthcare disparities.
Tekton Research has extensive experience conducting clinical trials in therapeutic areas such as Alzheimer's disease, migraine, vaccines, and others. Dr. David McCoy, a board-certified neurologist in Canadian County and a native Oklahoman, will serve as the principal investigator at the Yukon site. Dr. McCoy plays a key role in his community by providing accessible healthcare and maintaining strong relationships with his patients.

IGC Pharma Adds New Clinical Trial Site At Tekton Research In Yukon, Oklahoma, For Phase 2 CALMA Study Evaluating IGC-AD1 For Agitation In Alzheimer's Dementia

Wells Fargo analyst Richard Garchitorena upgrades FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) from Equal-Weight to Overweight and raises the price target from $41 to $50.

Upgrades

Wells Fargo Upgrades FMC to Overweight, Raises Price Target to $50

Buybacks

PRTH

Priority Technology Board Approves New $40M Share Repurchase Program

Deutsche Bank analyst David Begleiter maintains Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) with a Buy and raises the price target from $14 to $22.

Deutsche Bank Maintains Buy on Compass Minerals Intl, Raises Price Target to $22

<ul>
<li>The offering is being led by several preeminent global investment firms</li>
<li>Company total cash position expected to exceed $350 million following closing</li>
</ul>
HOBOKEN, N.J., June 23, 2025 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>), an innovative, integrated photonics and quantum optics technology company, today announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 14,035,089 shares of common stock in a private placement at a purchase price of $14.25 per share. The offering is expected to result in gross proceeds of $200 million, before deducting offering expenses. The closing of the offering is expected to occur on or about June 24, 2025, subject to the satisfaction of customary closing conditions.

Quantum Computing Announces Private Placement of 14M Shares at $14.25/Shr

GLJ Research analyst Austin Wang initiates coverage on GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Buy rating and announces Price Target of $702.

GLJ Research Initiates Coverage On GE Vernova with Buy Rating, Announces Price Target of $702

Digital Ally, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) today announced it has signed a Master Distribution Agreement (the "Agreement") with Redwood Scientific Technologies ("Redwood"), granting Digital Ally exclusive global rights to distribute Redwood's clinically-driven nicotine cessation products, including TBX-Free and TBX Vape-Free.
This Agreement establishes Digital Ally as the exclusive commercialization partner for a first-of-its-kind product designed to help Americans overcome addiction to vape devices. TBX Vape-Free, delivered via oral thin-film technology, is expected to be the first product of its kind to directly target vape-related nicotine dependency. This Agreement provides Digital Ally the exclusive global rights to Redwood's full range of technologies, brands, trademarks, manufacturing processes, vendor relationships, and additional essential assets.

DGLY

Digital Ally Sign Master Distribution Agreement With Redwood Scientific, Granting Digital Ally Exclusive Global Rights To Distribute Redwood's Clinically-Driven Nicotine Cessation Products, Including TBX-Free And TBX Vape-Free

Deutsche Bank analyst Paul Trussell maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Hold and raises the price target from $57 to $67.

Deutsche Bank Maintains Hold on Kroger, Raises Price Target to $67

Patient Treated with OneRF&#xAE; Ablation System Previously Experienced up to 10 Seizures a Day
EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that Clara—an early patient treated with the Company's patented OneRF&#xAE; Ablation System—has successfully surpassed the one year milestone of being seizure free.
Clara was one of the first patients to undergo treatment using NeuroOne's OneRF&#xAE; platform. Since the procedure in June 2024, Clara has been completely seizure-free, which has greatly improved her quality of life.

NMTC

NeuroOne Medical Technologies Patient Treated With Patented OneRF Ablation System Surpasses One Year Milestone Of Being Seizure Free

Scotiabank analyst Andres Coello downgrades AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) from Sector Outperform to Sector Perform and announces $45.4 price target.

Downgrades

ASTS

Scotiabank Downgrades AST SpaceMobile to Sector Perform, Announces $45.4 Price Target

Deutsche Bank analyst Steve Powers upgrades Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) from Hold to Buy and raises the price target from $71 to $95.

Comments

NuGen Medical Devices

Notizie

Ultime notizie per NuGen Medical Devices (OTC:NGMDF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO